Hidradenitis Suppurativa
2 stories
-
healthLutikizumab Shows Promise for Hidradenitis Suppurativa After Anti-TNF Failure
Phase 2 trial reveals lutikizumab improves outcomes in moderate-to-severe hidradenitis suppurativa patients unresponsive to anti-TNF therapy.
-
healthImmunodermatology: Novartis Podcast Unpacks Skin Health and Systemic Immunity
Novartis Pharma AG funded podcast 'ImmunoDerm Dialogues' explores immune-mediated skin diseases, T-cell dysregulation, and innovative treatments like BTK inhibition for conditions including lupus and HS.